Developer docs
API playgroundTry for free, no card

Search company profiles

Breethe

Full company profile

uuid00044ee

Namestring
Breethe
Websiteurl
breethe.life
Company typeenum
Private
Founded yearint
2014
Descriptiontext

Breethe is a Baltimore-based medical device company founded in 2014 that develops a compact artificial lung — the Breethe Oxy-1 System — designed to provide extracorporeal oxygenation for patients with acute and chronic lung problems. The system is positioned within cardiac care workflows, specifically supporting heart recovery, protected PCI, and cardiogenic shock management, where it complements Abiomed's Impella heart pump portfolio by oxygenating the body during cardiac procedures. As an 11-50 employee venture-backed company that raised approximately $18.4M across six funding rounds from 2015 to 2019, Breethe was acquired by Abiomed (now a Johnson & Johnson company) and is currently marketed through the HeartRecovery.com platform alongside Abiomed's broader heart recovery product line. The product is listed under "Future Innovations," indicating it remains in an early commercial phase within the larger Abiomed/J&J ecosystem.

The company's go-to-market is channeled through Abiomed's established cardiac care infrastructure, including a 24-hour clinical support hotline (1-800-422-8666) and global regional sites covering North America, Europe (Germany, France), and Asia Pacific (Japan). Customer concentration sits within hospitals performing high-acuity cardiac interventions, where the Breethe Oxy-1 System is deployed as part of integrated heart recovery protocols. The company does not disclose standalone pricing or revenue, and operates as a product line within Johnson & Johnson MedTech rather than as an independently reported entity.

Short descriptiontext

Breethe is a Baltimore-based medical device company developing the Breethe Oxy-1 System, a compact artificial lung that provides extracorporeal oxygenation for cardiac care patients. Acquired by Abiomed (now Johnson & Johnson), it is marketed to hospitals performing heart recovery, protected PCI, and cardiogenic shock procedures.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersBaltimore, United States
HQ citystring
Baltimore
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
medical devices, artificial lung, oxygenation system, respiratory support, cardiac care devices
Industry2 codes
PRIMARYHLAHAGAD
Oxygen Therapy Systems (Concentrators, Cylinders, Liquid O2, HFNC)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Respiratory & Sleep Therapy Devices
SECONDARYHLAKANAM
Home Ventilation, Oxygen Therapy & Respiratory DME Clinical Management
NAICS code1 code
  • Surgical Appliance and Supplies Manufacturing339113
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Medical Devices
No data
Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Breethe is a medical device company that develops a compact artificial lung (the Breethe Oxy-1 System) for patients with acute and chronic lung problems. The device provides extracorporeal oxygenation to support cardiac care procedures such as heart recovery, protected PCI, and cardiogenic shock management. The technology integrates into Abiomed's broader cardiac care ecosystem and is intended for use by healthcare professionals in hospital settings.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1Breethe Oxy-1 System
CategoryMedical Devices
Description

A compact artificial lung (extracorporeal oxygenation device) intended for patients with acute and chronic lung problems, providing oxygenation support during heart recovery procedures, protected PCI, and cardiogenic shock management. Sold to hospitals and used by healthcare professionals within the Abiomed/J&J cardiac care portfolio.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1Terumo (Terumo Cardiovascular / FX05)
TypeDirect peer
Description

Terumo Cardiovascular offers oxygenators and ECMO circuits (e.g., FX05 oxygenator, Terumo System 1) used in cardiopulmonary bypass and ECMO. Direct competitor in oxygenation consumables and systems for cardiac surgical and support applications.

2Nipro Corporation
TypeDirect peer
Description

Nipro manufactures hollow-fibre oxygenators and ECMO/ECCO2R systems (e.g., Biocon oxygenator) used in cardiac surgery and respiratory support. Directly comparable as an oxygenation device competitor.

TypeBroad incumbent
Description

Acquirer of Breethe and parent of the Oxy-1 system. Abiomed sells the Impella heart pump platform and now offers Breethe as part of its heart-recovery portfolio, making it the most directly aligned commercial vehicle for Breethe's oxygenation technology.

TypeDirect peer
Description

Through its TandemLife/TLS product line, LivaNova offers portable ECMO and oxygenation systems (including LifeSPARC controller) for cardiogenic shock and respiratory failure. Direct competitor in compact oxygenation/ECMO for cardiac care.

TypeDirect peer
Description

Getinge's Maquet Cardiohelp system is a leading portable ECMO/oxygenation platform used in cardiac surgery, cardiogenic shock, and respiratory failure. Directly competes with Breethe Oxy-1 in the compact oxygenation/ECMO category for cardiac and respiratory support.

TypeDirect peer
Description

Xenios (acquired by Fresenius) developed i-cor, iLA, and Novalung oxygenation/ECMO devices for cardiac and respiratory support, directly competing with Breethe Oxy-1 in the compact oxygenation category.

TypeBroad incumbent
Description

Medtronic manufactures oxygenators and ECMO-related disposables (Affinity Fusion, Nautilus) as part of its broader cardiac surgery portfolio. While not focused exclusively on compact oxygenation, it competes broadly in oxygenation consumables for cardiopulmonary support.

TypeEmerging player
Description

Inspira is developing compact extracorporeal blood oxygenation and CO2 removal systems (e.g., ART device) for respiratory failure and cardiac support, positioning itself as a next-generation compact oxygenation player similar in concept to Breethe Oxy-1.

TypeEmerging player
Description

Hemovent develops a portable, self-contained ECMO system (MOBYBOX) with a fully integrated oxygenator and pump, directly targeting the same compact-oxygenation, point-of-care use case as Breethe Oxy-1.

TypeEmerging player
Description

ALung developed the Hemolung Respiratory Assist System (RAS) for extracorporeal CO2 removal (ECCO2R), an adjacent compact respiratory support technology that overlaps with Breethe's oxygenation value proposition.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks4 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Breethe

Medical Devicesbreethe.life

Breethe is a Baltimore-based medical device company developing the Breethe Oxy-1 System, a compact artificial lung that provides extracorporeal oxygenation for cardiac care patients. Acquired by Abiomed (now Johnson & Johnson), it is marketed to hospitals performing heart recovery, protected PCI, and cardiogenic shock procedures.

What Breethe does

Breethe is a Baltimore-based medical device company founded in 2014 that develops a compact artificial lung — the Breethe Oxy-1 System — designed to provide extracorporeal oxygenation for patients with acute and chronic lung problems. The system is positioned within cardiac care workflows, specifically supporting heart recovery, protected PCI, and cardiogenic shock management, where it complements Abiomed's Impella heart pump portfolio by oxygenating the body during cardiac procedures. As an 11-50 employee venture-backed company that raised approximately $18.4M across six funding rounds from 2015 to 2019, Breethe was acquired by Abiomed (now a Johnson & Johnson company) and is currently marketed through the HeartRecovery.com platform alongside Abiomed's broader heart recovery product line. The product is listed under "Future Innovations," indicating it remains in an early commercial phase within the larger Abiomed/J&J ecosystem.

The company's go-to-market is channeled through Abiomed's established cardiac care infrastructure, including a 24-hour clinical support hotline (1-800-422-8666) and global regional sites covering North America, Europe (Germany, France), and Asia Pacific (Japan). Customer concentration sits within hospitals performing high-acuity cardiac interventions, where the Breethe Oxy-1 System is deployed as part of integrated heart recovery protocols. The company does not disclose standalone pricing or revenue, and operates as a product line within Johnson & Johnson MedTech rather than as an independently reported entity.

Breethe firmographics

Firmographics
Name
Breethe
Website
https://breethe.life
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
1–10 employees
Short description
Breethe is a Baltimore-based medical device company developing the Breethe Oxy-1 System, a compact artificial lung that provides extracorporeal oxygenation for cardiac care patients. Acquired by Abiomed (now Johnson & Johnson), it is marketed to hospitals performing heart recovery, protected PCI, and cardiogenic shock procedures.
Ownership category
akta.pro rank

Breethe industry classification

Industry
Product category
Medical Devices
NAICS
Surgical Appliance and Supplies Manufacturing (339113)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHAGAD
Oxygen Therapy Systems (Concentrators, Cylinders, Liquid O2, HFNC)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Respiratory & Sleep Therapy Devices
SECONDARYHLAKANAM
Home Ventilation, Oxygen Therapy & Respiratory DME Clinical Management

Keywords

  • Medical devices
  • Artificial lung
  • Oxygenation system
  • Respiratory support
  • Cardiac care devices

Where Breethe is headquartered

Location

Headquarters

HQ city
Baltimore
HQ country
United States
HQ region
North America

Markets served

Breethe business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Breethe product offering

Product offering

Core offering

Breethe is a medical device company that develops a compact artificial lung (the Breethe Oxy-1 System) for patients with acute and chronic lung problems. The device provides extracorporeal oxygenation to support cardiac care procedures such as heart recovery, protected PCI, and cardiogenic shock management. The technology integrates into Abiomed's broader cardiac care ecosystem and is intended for use by healthcare professionals in hospital settings.

Differentiator

Problem solved

Functional benefit

Products and services

  • Breethe Oxy-1 System A compact artificial lung (extracorporeal oxygenation device) intended for patients with acute and chronic lung problems, providing oxygenation support during heart recovery procedures, protected PCI, and cardiogenic shock management. Sold to hospitals and used by healthcare professionals within the Abiomed/J&J cardiac care portfolio.

Companies that use Breethe

Customer profile

Segments1 record

Ideal customer profiles1 record

Breethe technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Breethe partnerships and signals

Strategic signal

Recent moves6 records

Expansion highlights5 records

Breethe competitors and assessment

Company assessment

Direct peers

  • Terumo (Terumo Cardiovascular / FX05): Terumo Cardiovascular offers oxygenators and ECMO circuits (e.g., FX05 oxygenator, Terumo System 1) used in cardiopulmonary bypass and ECMO. Direct competitor in oxygenation consumables and systems for cardiac surgical and support applications.
  • Nipro Corporation: Nipro manufactures hollow-fibre oxygenators and ECMO/ECCO2R systems (e.g., Biocon oxygenator) used in cardiac surgery and respiratory support. Directly comparable as an oxygenation device competitor.
  • LivaNova (TandemLife / LifeSPARC): Through its TandemLife/TLS product line, LivaNova offers portable ECMO and oxygenation systems (including LifeSPARC controller) for cardiogenic shock and respiratory failure. Direct competitor in compact oxygenation/ECMO for cardiac care.
  • Getinge (Maquet Cardiohelp): Getinge's Maquet Cardiohelp system is a leading portable ECMO/oxygenation platform used in cardiac surgery, cardiogenic shock, and respiratory failure. Directly competes with Breethe Oxy-1 in the compact oxygenation/ECMO category for cardiac and respiratory support.
  • Fresenius Medical Care / Xenios (now part of Fresenius): Xenios (acquired by Fresenius) developed i-cor, iLA, and Novalung oxygenation/ECMO devices for cardiac and respiratory support, directly competing with Breethe Oxy-1 in the compact oxygenation category.

Broad incumbents

  • Abiomed (Johnson & Johnson MedTech): Acquirer of Breethe and parent of the Oxy-1 system. Abiomed sells the Impella heart pump platform and now offers Breethe as part of its heart-recovery portfolio, making it the most directly aligned commercial vehicle for Breethe's oxygenation technology.
  • Medtronic (Affinity Fusion oxygenator): Medtronic manufactures oxygenators and ECMO-related disposables (Affinity Fusion, Nautilus) as part of its broader cardiac surgery portfolio. While not focused exclusively on compact oxygenation, it competes broadly in oxygenation consumables for cardiopulmonary support.

Emerging players

  • Inspira Technologies: Inspira is developing compact extracorporeal blood oxygenation and CO2 removal systems (e.g., ART device) for respiratory failure and cardiac support, positioning itself as a next-generation compact oxygenation player similar in concept to Breethe Oxy-1.
  • Hemovent: Hemovent develops a portable, self-contained ECMO system (MOBYBOX) with a fully integrated oxygenator and pump, directly targeting the same compact-oxygenation, point-of-care use case as Breethe Oxy-1.
  • ALung Technologies: ALung developed the Hemolung Respiratory Assist System (RAS) for extracorporeal CO2 removal (ECCO2R), an adjacent compact respiratory support technology that overlaps with Breethe's oxygenation value proposition.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks4 records

Key highlights6 records

Customer concentration

Breethe financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Breethe leadership team

Management profile

Number of profiles

Profiles2 records

Breethe funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Breethe M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Breethe

What does Breethe do?

Breethe is a medical device company that develops a compact artificial lung (the Breethe Oxy-1 System) for patients with acute and chronic lung problems. The device provides extracorporeal oxygenation to support cardiac care procedures such as heart recovery, protected PCI, and cardiogenic shock management. The technology integrates into Abiomed's broader cardiac care ecosystem and is intended for use by healthcare professionals in hospital settings.

Is Breethe a public or private company?

Breethe is a private company. It is classified as corporate owned and is currently operating.

When was Breethe founded?

Breethe was founded in 2014. It employs 1 to 10 people.

Where is Breethe based?

Breethe is headquartered in Baltimore, United States, in the North America region.

Who are Breethe's main competitors?

Direct peers on record are Terumo (Terumo Cardiovascular / FX05), Nipro Corporation, LivaNova (TandemLife / LifeSPARC), Getinge (Maquet Cardiohelp) and Fresenius Medical Care / Xenios (now part of Fresenius). Broad incumbents are Abiomed (Johnson & Johnson MedTech) and Medtronic (Affinity Fusion oxygenator). Emerging players are Inspira Technologies, Hemovent and ALung Technologies.

Does Breethe have an API?

No public API is recorded for Breethe.

What industry is Breethe in?

Breethe's product category is Medical Devices. Its primary akta.pro industry code is HLAHAGAD, Oxygen Therapy Systems (Concentrators, Cylinders, Liquid O2, HFNC), with a secondary code of HLAKANAM, Home Ventilation, Oxygen Therapy & Respiratory DME Clinical Management. Its NAICS code is 339113 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals